This retrospective study took a closer look at intermediate risk patients, dividing them into favorable and unfavorable intermediate risk. Only the unfavorable intermediate risk guys benefitted from the brachy boost. The price for that was a higher risk of late-term urinary toxicity (which was lasting in only one patient).
/pcnrv.blogspot.com/2017/05/brachy-boost-therapy-should-be-reserved.html